Gum Arabic nanoformulation rescues neuronal lesions in bromobenzene-challenged rats by its antioxidant, anti-apoptotic and cytoprotective potentials.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Gum Arabic* ; Antioxidants*/pharmacology; Male ; Animals ; Rats ; Rats, Wistar

Bromobenzene (BB) is a hazardous environmental contaminant because of its multiple routes of exposure and the toxicity of its bio-derivates. It could elicit neuronal alterations by stimulating redox imbalance and apoptotic pathways. Gum Arabic (GA) protected the hippocampus of a type 2 diabetic rat model from cognitive decline. Whether gum Arabic nanoemulsion (GANE) can increase the neuroprotectant potency of GA in fighting BB-associated neurological lesions is the question to be answered. To accomplish this objective, 25 adult male Wistar rats were randomly and equally assigned into five groups. Control received olive oil (vehicle of BB). BB group received BB at a dose of 460 mg/kg BW. Blank nanoemulsion (BNE) group supplemented with BNE at 2 mL of 10% w/v aqueous suspension/kg BW. GANE group received GANE at a dose of 2 mL of 10% w/v aqueous suspension/kg BW. BB + GANE group exposed to BB in concomitant with GANE at the same previous doses. All interventions were carried out daily by oral gavage for ten consecutive days. BB caused a marked increase in malondialdehyde and succinate dehydrogenase together with a marked decrease in reduced glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, catalase, and lactate dehydrogenase in the brain. BB was accompanied by pathological deteriorations, amyloidosis, and reduced immuno-expression of integrase interactor 1 in the hippocampal region. Administration of GANE was beneficial in reversing the aforementioned abnormalities. These results pave the road for further discovery of nano-formulated natural products to counter the threats of BB.
(© 2022. The Author(s).)

Cell Biol Toxicol. 2016 Oct;32(5):373-90. (PMID: 27250656)
Nutr Cancer. 2022;74(3):956-964. (PMID: 34085880)
J Nanobiotechnology. 2018 Sep 19;16(1):71. (PMID: 30231877)
Food Chem Toxicol. 2009 Jul;47(7):1584-90. (PMID: 19371770)
J Biol Chem. 1985 Oct 25;260(24):13035-40. (PMID: 2932433)
J Biol Chem. 1972 May 25;247(10):3170-5. (PMID: 4623845)
Aquat Toxicol. 2019 Feb;207:83-90. (PMID: 30537592)
Redox Biol. 2018 Apr;14:450-464. (PMID: 29080524)
J Exp Med. 1997 Apr 21;185(8):1481-6. (PMID: 9126928)
Eur J Pharmacol. 2011 Jan 10;650(1):184-94. (PMID: 20868662)
J Physiol. 1996 Feb 1;490 ( Pt 3):783-92. (PMID: 8683476)
J Neurochem. 2006 Jun;97(6):1634-58. (PMID: 16805774)
AAPS J. 2009 Dec;11(4):693-9. (PMID: 19842043)
Bosn J Basic Med Sci. 2010 Feb;10(1):83-8. (PMID: 20192938)
Nutr Cancer. 2010;62(6):802-10. (PMID: 20661830)
Chem Biol Interact. 2016 Jul 25;254:117-23. (PMID: 27270452)
Appl Biochem Biotechnol. 2020 Feb;190(2):616-633. (PMID: 31407161)
Chem Res Toxicol. 1998 Jun;11(6):604-7. (PMID: 9625727)
Nat Rev Neurosci. 2014 Dec;15(12):771-85. (PMID: 25387473)
Mol Cancer. 2009 Jun 05;8:32. (PMID: 19497135)
Mov Disord. 2018 Oct;33(10):1580-1590. (PMID: 30294923)
J Vasc Surg. 2003 Dec;38(6):1283-92. (PMID: 14681629)
Redox Biol. 2018 May;15:490-503. (PMID: 29413961)
J Exp Biol. 2004 Aug;207(Pt 18):3189-200. (PMID: 15299040)
Toxicol Appl Pharmacol. 1993 Oct;122(2):191-9. (PMID: 8212001)
Clin Exp Metastasis. 2005;22(1):25-30. (PMID: 16132575)
Toxicology. 1998 Apr 3;126(3):213-22. (PMID: 9674969)
J Food Sci. 2018 Feb;83(2):509-516. (PMID: 29337369)
Genet Med. 2015 Apr;17(4):313-4. (PMID: 25835194)
Biochem Pharmacol. 2003 Mar 1;65(5):857-75. (PMID: 12628495)
J Chem Neuroanat. 2022 Mar;120:102060. (PMID: 34915150)
J Biol Chem. 2003 Aug 15;278(33):31426-33. (PMID: 12775726)
Pathol Int. 2015 Jan;65(1):9-18. (PMID: 25414046)
Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108349. (PMID: 34083037)
Eur Rev Med Pharmacol Sci. 2013 Mar;17(5):569-81. (PMID: 23543440)
Pharmacology. 1974;11(3):151-69. (PMID: 4831804)
J Neurochem. 2002 Jan;80(1):91-100. (PMID: 11796747)
Nat Rev Mol Cell Biol. 2003 Jul;4(7):552-65. (PMID: 12838338)
Hepatology. 1998 Mar;27(3):748-54. (PMID: 9500703)
Neurobiol Dis. 2015 Dec;84:109-19. (PMID: 26102023)
Neurosurg Focus. 2006 Jan 15;20(1):E11. (PMID: 16459991)
J Integr Med. 2015 Mar;13(2):115-21. (PMID: 25797642)
Toxicol Rep. 2014 Aug 27;1:629-638. (PMID: 28962276)
Clin Cancer Res. 2002 Nov;8(11):3461-7. (PMID: 12429635)
Cell Death Dis. 2019 Sep 10;10(9):653. (PMID: 31506428)
Br Med Bull. 1993 Jul;49(3):566-76. (PMID: 8221023)
Ren Fail. 2003 Jan;25(1):15-20. (PMID: 12617329)
Cell Mol Life Sci. 2019 Oct;76(20):4023-4042. (PMID: 31236625)
Pathophysiology. 2015 Dec;22(4):189-94. (PMID: 26321624)
Anal Biochem. 1978 May;86(1):271-8. (PMID: 655387)
J Neurosci. 2004 Mar 10;24(10):2401-11. (PMID: 15014115)
Pharmaceutics. 2020 Jan 16;12(1):. (PMID: 31963155)
Adv Colloid Interface Sci. 2019 Jul;269:277-295. (PMID: 31132673)
Appl Microbiol Biotechnol. 2003 Nov;63(1):10-21. (PMID: 12802529)
Methods Enzymol. 1984;105:121-6. (PMID: 6727660)
J Biol Chem. 1991 Mar 15;266(8):5049-54. (PMID: 2002047)
Redox Biol. 2013 Jan 11;1:24-31. (PMID: 24024135)
J Biol Chem. 1951 Nov;193(1):265-75. (PMID: 14907713)
Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):276-91. (PMID: 18090434)

9000-01-5 (Gum Arabic)
0 (Antioxidants)

Date Created: 20221209 Date Completed: 20221215 Latest Revision: 20230112

20231215

PMC9731957

10.1038/s41598-022-24556-0

36481816